Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naïve patient: A report of three cases

Oncology Letters

Volumn 7, Issue 2, 2014, Pages 357-360

  Yamaguchi, Fumihiro ^a,b   Fukuchi, Kunihiko ^b   Yamazaki, Yohei ^a   Takayasu, Hiromi ^a   Tazawa, Sakiko ^a   Tateno, Hidetsugu ^a,b   Kato, Eisuke ^a   Wakabayashi, Aya ^a   Fujimori, Mami ^a   Iwasaki, Takuya ^a   Hayashi, Makoto ^a   Tsuchiya, Yutaka ^a   Yamashita, Jun ^a   Takeda, Norikazu ^a   Kokubu, Fumio ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitor resistance mutation; L747S; Small cell lung carcinoma; Small cell lung carcinomaL747S

Indexed keywords

CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEMCITABINE; GENOMIC DNA; PROGASTRIN RELEASING PEPTIDE; TUMOR MARKER;

AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; GENE MUTATION; GENE SEQUENCE; HUMAN; HYPONATREMIA; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; SMOKING; THORAX RADIOGRAPHY; VERY ELDERLY;

EID: 84890352969     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1705     Document Type: Article

References (23)

1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, OizumiS, etal: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
2. Mitsudomi T, Morita S, Yatabe Y, Negoro S, OkamotoI, etal: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
3. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742, 2011.
4. Rosell R, Carcereny E, Gervais R, Vergnenegre A, MassutiB, etal: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol13: 239-246, 2012.
5. Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180, 2011.
6. Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824, 2007.
7. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, etal: Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 126: 651-655, 2010.
8. Lin L and Bivona TG: Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract: 2012: 817297, 2012.
9. Suda K, Mizuuchi H, Maehara Y and Mitsudomi T: Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev31: 807-814, 2012.
10. Yamaguchi F, Kugawa S, Tateno H, Kokubu F and Fukuchi K: Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. Lung Cancer 78: 201-206, 2012.
11. Pallis AG, Voutsina A, Kalikaki A, Souqlakos J, Briasoulis E, etal: 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 97: 1560-1566, 2007.
12. Jia XL and Chen G: EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. Lung Cancer 74: 396-400, 2011.
13. Costa DB, Schumer ST, Tenen DG and Kobayashi S: Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. JClin Oncol 26: 1182-1184, 2008.
14. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, etal: Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 14: 7060-7067, 2008.
15. Goto K, Satouchi M, Ishii G, Nishio K, Hagiwara K, et al: An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 23: 2914-2919, 2012.
16. Fukui T, Tsuta K, Furuta K, Watanabe S, Asamura H, etal: Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci 98: 1714-1719, 2007.
17. Morinaga R, Okamoto I, Furuta K, Kawano Y, Sekijima M, etal: Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 58: 411-413, 2007.
18. Tatematsu A, Shimizu J, Murakami Y, Horio Y, NakamuraS, etal: Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 14: 6092-6096, 2008.
19. Zakowski MF, Ladanyi M and Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group: EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355: 213-215, 2006.
20. Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K and Fukuoka M: EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 17: 1028-1029, 2006.
21. Lu HY, Mao WM, Cheng QY, Chen B, Cai JF, et al: Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. Oncol Lett 3: 1288-1292, 2012.
22. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, TurkeAB, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med3: 75ra26, 2011.
23. Alam N, Gustafson KS, Ladanyi M, Zakowski MF, KapoorA, etal: Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin lung Cancer 11: E1-E4, 2010.